CVSNYSERetail-Drug Stores and Proprietary StoresFiscal year ends December 31
CVS HEALTH Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$92.68+0.32 (+0.35%)
Close on Oct 19, 2026
- Market cap
- $119.28B
- P/E (TTM)
- 24.6
- Dividend yield
- 2.87%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
89.2%
1.14B of 1.28B shares
Institutional holders
2,064
323 new, 108 sold out
Net institutional buying
39M
In Q2 2026
Insider trades, 12 months
0 buys · 8 sales
Net sold $323.71M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Vanguard Capital Management | 95,598,528 | 7.51% | 13G (passive) | Mar 31, 2026 |
| Capital World Investors | 68,785,990 | 5.50% | 13G (passive) | Mar 31, 2025 |
| BlackRock, Inc. | 105,292,588 | 8.30% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CVS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 123,223,409 | 9.63% | $12.75B | −2,696,444 | 0.19% |
| Vanguard Capital Management LLC | 83,315,369 | 6.51% | $8.62B | +665,293 | 0.18% |
| Capital World Investors | 74,951,955 | 5.86% | $7.75B | −2,296,687 | 0.92% |
| State Street Corp | 60,283,408 | 4.71% | $6.24B | +961,227 | 0.18% |
| Dodge & Cox | 50,012,765 | 3.91% | $5.17B | −1,767,351 | 2.71% |
| Wellington Management Group Llp | 33,801,113 | 2.64% | $3.50B | +11,233,381 | 0.60% |
| Geode Capital Management, LLC | 29,899,653 | 2.34% | $3.08B | +440,611 | 0.16% |
| FMR LLC | 28,920,617 | 2.26% | $2.99B | −2,276,273 | 0.13% |
| Vanguard Portfolio Management LLC | 26,637,259 | 2.08% | $2.76B | +639,911 | 0.12% |
| Capital Research Global Investors | 24,329,151 | 1.90% | $2.52B | +4,316,819 | 0.35% |
| Price T Rowe Associates Inc /Md/ | 24,203,884 | 1.89% | $2.50M | +420,739 | 0.25% |
| Bank Of America Corp /De/ | 23,188,670 | 1.81% | $2.40B | +13,836,701 | 0.15% |
| JPMorgan Chase & Co | 22,112,970 | 1.73% | $2.29B | −7,414,155 | 0.13% |
| Invesco Ltd. | 20,595,431 | 1.61% | $2.13B | −4,543,515 | 0.17% |
| Morgan Stanley | 18,606,028 | 1.45% | $1.92B | +780,906 | 0.10% |
| Norges Bank | 18,038,922 | 1.41% | $1.87B | New | 0.19% |
| Capital International Investors | 15,387,600 | 1.20% | $1.59B | −4,622 | 0.33% |
| Goldman Sachs Group Inc | 13,411,807 | 1.05% | $1.39B | +772,006 | 0.12% |
| Charles Schwab Investment Management Inc | 13,259,314 | 1.04% | $1.37B | −415,611 | 0.18% |
| Davis Selected Advisers | 11,865,916 | 0.93% | $1.23B | −373,750 | 5.27% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 2,064 | 1.14B | 89.2% | 323 / 778 | 732 / 108 | 114M | 74M |
| Q1 2026 | 1,877 | 1.11B | 86.4% | 159 / 726 | 747 / 197 | 201M | 105M |
| Q4 2025 | 1,948 | 1.14B | 88.7% | 272 / 704 | 723 / 119 | 100M | 92M |
| Q3 2025 | 1,838 | 1.13B | 88.3% | 213 / 670 | 726 / 109 | 98M | 72M |
| Q2 2025 | 1,760 | 1.11B | 86.4% | 184 / 636 | 730 / 157 | 92M | 70M |
| Q1 2025 | 1,754 | 1.08B | 84.8% | 278 / 536 | 756 / 170 | 116M | 77M |
| Q4 2024 | 1,670 | 1.05B | 82.1% | 231 / 370 | 932 / 368 | 125M | 103M |
| Q3 2024 | 1,844 | 1.03B | 80.8% | 158 / 490 | 1012 / 207 | 181M | 86M |
| Q2 2024 | 1,914 | 1.04B | 81.3% | 131 / 574 | 1044 / 371 | 137M | 173M |
| Q1 2024 | 2,182 | 1.08B | 84.3% | 132 / 780 | 1048 / 180 | 79M | 64M |
| Q4 2023 | 2,263 | 1.07B | 83.3% | 308 / 668 | 1094 / 126 | 112M | 47M |
| Q3 2023 | 2,118 | 1.00B | 78.3% | 110 / 783 | 1024 / 173 | 86M | 82M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CVS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 40,502,867 | 3.17% | $4.19B | 0.18% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 33,064,695 | 2.59% | $3.42B | 0.20% | Jun 30, 2026 |
| Dodge & Cox Stock Fund | 31,708,094 | 2.48% | $3.28B | 2.77% | Jun 30, 2026 |
| Washington Mutual Investors Fund | 31,634,083 | 2.47% | $3.30B | 1.52% | Jul 31, 2026 |
| Income Fund of America | 23,692,996 | 1.85% | $2.47B | 1.67% | Jul 31, 2026 |
| American Balanced Fund | 17,930,421 | 1.40% | $1.85B | 0.64% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 17,551,259 | 1.37% | $1.82B | 0.20% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 16,280,513 | 1.27% | $1.48B | 0.18% | May 31, 2026 |
| Vanguard Value Index Fund | 12,146,799 | 0.95% | $1.26B | 0.49% | Jun 30, 2026 |
| American Mutual Fund | 10,479,452 | 0.82% | $1.09B | 0.93% | Jul 31, 2026 |
| Vanguard Health Care Fund | 9,210,092 | 0.72% | $961.81M | 2.52% | Jul 31, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 9,013,998 | 0.70% | $932.50M | 2.30% | Jun 30, 2026 |
| American Funds Fundamental Investors | 8,500,940 | 0.66% | $879.42M | 0.49% | Jun 30, 2026 |
| Vanguard Institutional Index Fund | 6,926,554 | 0.54% | $716.55M | 0.20% | Jun 30, 2026 |
| Vanguard Equity Income Fund | 6,245,709 | 0.49% | $646.12M | 0.99% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| J. David Joyner | President, CEO and Chair, Director | 70,349 | 0.01% | Apr 2, 2026 |
| James David Clark | SVP, Cont & Chief Acct Officer | 27,606 | 0.00% | Jun 29, 2026 |
| Amy Compton-Phillips | EVP, Chief Medical Officer | 9,592 | 0.00% | Jun 1, 2026 |
| Brian Newman | EVP, Chief Financial Officer | 3,038 | 0.00% | Jun 1, 2026 |
| Tilak Mandadi | EVP, Chief Exp & Tech Officer | 10,133 | 0.00% | May 11, 2026 |
| Prem S. Shah | EVP and Group President | 64,356 | 0.01% | Apr 2, 2026 |
| Steven H. Nelson | EVP and President, Aetna | 2,924 | 0.00% | Apr 2, 2026 |
| Samrat S. Khichi | EVP, CPO and General Counsel | 33,421 | 0.00% | Apr 2, 2026 |
| Heidi B. Capozzi | EVP and Chief People Officer | 13,108 | 0.00% | Apr 2, 2026 |
| Thomas F. Cowhey | EVP and CFO | 41,109 | 0.00% | Apr 3, 2025 |
| Fernando Aguirre | Director | 11,181 | 0.00% | May 22, 2026 |
| Larry Robbins | Director | 4,824,799 | 0.38% | May 21, 2026 |
| C. David Brown Ii | Director | 129,316 | 0.01% | May 15, 2026 |
| J. Scott Kirby | Director | 14,434 | 0.00% | May 15, 2026 |
| Guy P. Sansone | Director | 15,106 | 0.00% | May 15, 2026 |
| John E. Gallina | Director | 582 | 0.00% | May 15, 2026 |
| Michael F. Mahoney | Director | 6,555 | 0.00% | May 15, 2026 |
| Leslie V. Norwalk | Director | 7,376 | 0.00% | May 15, 2026 |
| Anne A. Finucane | Director | 22,747 | 0.00% | May 15, 2026 |
| Alecia A. Decoudreaux | Director | 2,970 | 0.00% | May 15, 2026 |
| Douglas H. Shulman | Director | 5,929 | 0.00% | May 15, 2026 |
| Jeffrey R. Balser | Director | 15,717 | 0.00% | May 15, 2026 |
| Roger N. Farah | Director | 19,438 | 0.00% | Dec 2, 2025 |
| Nancy Ann Deparle | Director | 34,169 | 0.00% | Nov 25, 2024 |
| Mary L. Schapiro | Director | 11,844 | 0.00% | Nov 25, 2024 |
| Jean Pierre Millon | Director | 112,217 | 0.01% | Nov 25, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| James David Clark SVP, Cont & Chief Acct Officer | Jun 26, 2026 | Tax withholding | −454 | $90.98 | $41.30K | 27,606 |
| Brian Newman EVP, Chief Financial Officer | May 31, 2026 | Tax withholding | −2,478 | $90.98 | $225.45K | 3,008 |
| Amy Compton-Phillips EVP, Chief Medical Officer | May 31, 2026 | Tax withholding | −7,618 | $90.98 | $693.09K | 9,557 |
| Fernando Aguirre Director | May 21, 2026 | Returned to company | −1,563 | $93.50 | $146.14K | 10,513 |
| Larry Robbins Director | May 21, 2026 | Sale | −370,462 | $93.45 | $34.62M | 4,824,799 |
| Fernando Aguirre Director | May 20, 2026 | Returned to company | −30,437 | $93.78 | $2.85M | 12,076 |
| Larry Robbins Director | May 20, 2026 | Sale | −152,691 | $94.81 | $14.48M | 5,262,942 |
| Larry Robbins Director | May 20, 2026 | Sale | −797,628 | $93.48 | $74.56M | 5,415,633 |
| Larry Robbins Director | May 20, 2026 | Sale | −800 | $96.28 | $77.02K | 5,195,261 |
| Larry Robbins Director | May 20, 2026 | Sale | −66,881 | $95.67 | $6.40M | 5,196,061 |
| Larry Robbins Director | May 19, 2026 | Sale | −151 | $95.18 | $14.37K | 6,213,261 |
| Larry Robbins Director | May 19, 2026 | Sale | −1,983,387 | $94.45 | $187.33M | 6,213,412 |
| Guy P. Sansone Director | May 14, 2026 | Award | +1,447 | $97.15 | $140.58K | 15,106 |
| Leslie V. Norwalk Director | May 14, 2026 | Award | +1,447 | $97.15 | $140.58K | 7,376 |
| J. Scott Kirby Director | May 14, 2026 | Award | +1,447 | $97.15 | $140.58K | 14,434 |
| Fernando Aguirre Director | May 14, 2026 | Award | +1,563 | $97.15 | $151.85K | 42,513 |
| C. David Brown Ii Director | May 14, 2026 | Award | +1,544 | $97.15 | $150.00K | 129,316 |
| Jeffrey R. Balser Director | May 14, 2026 | Award | +2,058 | $97.15 | $199.93K | 15,717 |
| Tilak Mandadi EVP, Chief Exp & Tech Officer | May 8, 2026 | Sale | −69,551 | $89.58 | $6.23M | 10,133 |
| Tilak Mandadi EVP, Chief Exp & Tech Officer | Apr 1, 2026 | Tax withholding | −3,634 | $72.49 | $263.43K | 79,684 |
| Heidi B. Capozzi EVP and Chief People Officer | Apr 1, 2026 | Tax withholding | −1,334 | $72.49 | $96.70K | 13,023 |
| Samrat S. Khichi EVP, CPO and General Counsel | Apr 1, 2026 | Tax withholding | −3,541 | $72.49 | $256.69K | 33,421 |
| Steven H. Nelson EVP and President, Aetna | Apr 1, 2026 | Tax withholding | −2,432 | $72.49 | $176.30K | 2,900 |
| James David Clark SVP, Cont & Chief Acct Officer | Apr 1, 2026 | Tax withholding | −3,262 | $72.49 | $236.46K | 15,457 |
| J. David Joyner President, CEO and Chair, Director | Apr 1, 2026 | Tax withholding | −8,029 | $72.49 | $582.02K | 70,349 |
| Prem S. Shah EVP and Group President | Apr 1, 2026 | Tax withholding | −1,484 | $72.49 | $107.58K | 64,356 |
| Tilak Mandadi EVP, Chief Exp & Tech Officer | Mar 31, 2026 | Award | +22,277 | $71.82 | $1.60M | 88,543 |
| Brian Newman EVP, Chief Financial Officer | Mar 31, 2026 | Award | +19,493 | $71.82 | $1.40M | 41,354 |
| Heidi B. Capozzi EVP and Chief People Officer | Mar 31, 2026 | Award | +10,025 | $71.82 | $720.00K | 84,450 |
| Samrat S. Khichi EVP, CPO and General Counsel | Mar 31, 2026 | Award | +12,531 | $71.82 | $899.98K | 38,139 |
| Steven H. Nelson EVP and President, Aetna | Mar 31, 2026 | Award | +22,277 | $71.82 | $1.60M | 43,606 |
| James David Clark SVP, Cont & Chief Acct Officer | Mar 31, 2026 | Award | +11,138 | $71.82 | $799.93K | 35,539 |
| J. David Joyner President, CEO and Chair, Director | Mar 31, 2026 | Award | +86,326 | $71.82 | $6.20M | 160,860 |
| Amy Compton-Phillips EVP, Chief Medical Officer | Mar 31, 2026 | Award | +5,569 | $71.82 | $399.97K | 58,660 |
| Prem S. Shah EVP and Group President | Mar 31, 2026 | Award | +25,062 | $71.82 | $1.80M | 62,852 |
| John E. Gallina Director | Mar 19, 2026 | Award | +582 | $71.86 | $41.82K | 582 |
| J. David Joyner President and CEO, Director | Feb 28, 2026 | Tax withholding | −1,944 | $79.90 | $155.33K | 49,996 |
| Samrat S. Khichi EVP, CPO and General Counsel | Feb 28, 2026 | Tax withholding | −7,886 | $79.60 | $627.73K | 29,775 |
| Prem S. Shah EVP and Group President | Jan 1, 2026 | Tax withholding | −247 | $80.13 | $19.79K | 61,509 |
| James David Clark SVP, Cont & Chief Acct Officer | Dec 1, 2025 | Tax withholding | −220 | $79.10 | $17.40K | 24,401 |
| Roger N. Farah Director | Nov 30, 2025 | Tax withholding | −9,748 | $80.36 | $783.35K | 19,438 |
| Heidi B. Capozzi EVP and Chief People Officer | Nov 30, 2025 | Tax withholding | −9,470 | $80.36 | $761.01K | 11,415 |
| Tilak Mandadi EVP, Chief Exp & Tech Officer | Nov 30, 2025 | Tax withholding | −6,575 | $80.36 | $528.37K | 74,085 |
| Jeffrey R. Balser Director | Nov 20, 2025 | Award | +1,775 | $76.04 | $134.97K | 13,659 |
| Leslie V. Norwalk Director | Nov 20, 2025 | Award | +1,652 | $76.04 | $125.62K | 5,929 |
| C. David Brown Ii Director | Nov 20, 2025 | Award | +1,775 | $76.04 | $134.97K | 127,772 |
| J. Scott Kirby Director | Nov 20, 2025 | Award | +1,652 | $76.04 | $125.62K | 12,987 |
| Douglas H. Shulman Director | Nov 20, 2025 | Award | +1,652 | $76.04 | $125.62K | 5,929 |
| Fernando Aguirre Director | Nov 20, 2025 | Award | +1,800 | $76.04 | $136.87K | 40,950 |
| Anne A. Finucane Director | Nov 20, 2025 | Award | +591 | $76.04 | $44.94K | 591 |
| Guy P. Sansone Director | Nov 20, 2025 | Award | +1,652 | $76.04 | $125.62K | 13,659 |
| Prem S. Shah EVP and Group President | Aug 31, 2025 | Tax withholding | −6,995 | $73.15 | $511.68K | 60,632 |
| Tilak Mandadi EVP, Chief Exp & Tech Officer | Aug 31, 2025 | Tax withholding | −12,834 | $73.15 | $938.81K | 63,952 |
| Anne A. Finucane Director | Aug 20, 2025 | Sale | −7,500 | $71.02 | $532.65K | 22,156 |
| Guy P. Sansone Director | Jun 5, 2025 | Buy | +1,570 | $63.70 | $100.01K | 12,007 |
| Brian Newman EVP, Chief Financial Officer | May 31, 2025 | Award | +21,861 | $64.04 | $1.40M | 21,861 |
| Amy Compton-Phillips EVP, Chief Medical Officer | May 31, 2025 | Award | +6,246 | $64.04 | $399.99K | 53,091 |
| Amy Compton-Phillips EVP, Chief Medical Officer | May 31, 2025 | Award | +46,845 | $64.04 | $3.00M | 46,845 |
| Guy P. Sansone Director | May 15, 2025 | Award | +2,077 | $60.47 | $125.60K | 10,437 |
| Jeffrey R. Balser Director | May 15, 2025 | Award | +2,232 | $60.47 | $134.97K | 11,884 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Fernando Aguirre Director | May 22, 2026 | 32,000 | $3.03M | May 20, 2026 | Compensation |
| Roger N. Farah Director | May 21, 2026 | 2,817 | $263.89K | May 21, 2026 | Compensation |
| Mandadi Tilak Officer | May 8, 2026 | 69,551 | $6.23M | May 8, 2026 | Restricted Stock |
| Anne A. Finucane Director | Aug 19, 2025 | 7,500 | $532.28K | Aug 20, 2025 | Director Compensation |
| James David Clark Officer | Mar 5, 2025 | 7,513 | $498.49K | Mar 5, 2025 | STOCK OPTION EXERCISE |
| S. Shah Prem Officer | Feb 16, 2024 | 29,473 | $2.27M | Feb 16, 2024 | DRIP |
| James David Clark Officer | Aug 3, 2023 | 25,759 | $1.93M | Aug 3, 2023 | RESTRICTED STOCK |